Drugs / T1h
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02649270 | Oct 2014 → Jun 2015 | psoriasis | Biotech Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T1h | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02649270 ↗ |
| Modality | Monoclonal antibody | “humanized recombinant anti-CD6 monoclonal antibody” NCT02649270 ↗ |
| Route | Intravenous | “by vein” NCT02649270 ↗ |